Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Endocrinology & Metabolism

• Publication date

  2016-02-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/17446651.2016.1131119PMID 30058874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

  2015cited by this paper
• Weight gain and antipsychotics: a drug safety review

  2015cited by this paper
• Change in Sleep Duration and Type 2 Diabetes: The Whitehall II Study

  2015cited by this paper
• Mismatch of Sleep and Work Timing and Risk of Type 2 Diabetes

  2015cited by this paper
• Glycosylated hemoglobin as a screening test for hyperglycemia in antipsychotic-treated patients: a follow-up study

  2015cited by this paper
• Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus

  2015cited by this paper
• Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans

  2015cited by this paper
• Pathogenesis of Type 2 Diabetes Mellitus

  2015cited by this paper
• Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study

  2015cited by this paper
• Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis.

  2015cited by this paper
• Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis

  2015cited by this paper
• Autonomic regulation of hepatic glucose production.

  2014cited by this paper
• The brain modulates insulin sensitivity in multiple tissues.

  2014cited by this paper
• Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes.

  2014cited by this paper
• The cardiovascular effects of insulin

  2014cited by this paper
• The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

  2014cited by this paper
• Favourable effects of consuming a Palaeolithic-type diet on characteristics of the metabolic syndrome: a randomized controlled pilot-study

  2014cited by this paper
• Circadian insights into dopamine mechanisms.

  2014cited by this paper
• Seasonal Variations of Severe Hypoglycemia in Patients With Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and Non-diabetes Mellitus

  2014cited by this paper
• Circadian Misalignment Augments Markers of Insulin Resistance and Inflammation, Independently of Sleep Loss

  2014cited by this paper
• Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

  2014cited by this paper
• A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.

  2014cited by this paper
• β-Cell function in type 2 diabetes.

  2014cited by this paper
• Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies

  2014cited by this paper
• Pathway-selective Insulin Resistance and Metabolic Disease: The Importance of Nutrient Flux*

  2014cited by this paper
• Circadian control of glucose metabolism

  2014cited by this paper
• Nitric Oxide, Oxidative Stress, and p66Shc Interplay in Diabetic Endothelial Dysfunction

  2014cited by this paper
• Circadian regulation of metabolism.

  2014cited by this paper
• Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder.

  2014cited by this paper
• Hypothalamic glucose sensing: making ends meet

  2014cited by this paper
• Melatonin, energy metabolism, and obesity: a review

  2014cited by this paper
• Physiological and pathophysiological implications of lipid sensing in the brain

  2014cited by this paper
• Circadian Patterns of ST Elevation Myocardial Infarction in the New Millennium

  2013cited by this paper
• Administration-Time Differences in Effects of Hypertension Medications on Ambulatory Blood Pressure Regulation

  2013cited by this paper
• Diagnosing vascular variability anomalies, not only MESOR-hypertension.

  2013cited by this paper
• New dynamics in global obesity facing low- and middle-income countries

  2013cited by this paper
• Extracellular Signal–Regulated Kinase in the Ventromedial Hypothalamus Mediates Leptin-Induced Glucose Uptake in Red-Type Skeletal Muscle

  2013cited by this paper
• Involvement of dopamine D2 receptors activation in ischemic post-conditioning-induced cardioprotection through promoting PKC-ε particulate translocation in isolated rat hearts

  2013cited by this paper
• During winter the body resists insulin

  2013cited by this paper
• Hypothalamic Role in the Insulin Resistance Syndrome

  2013cited by this paper
• Association of seasonal variation in the prevalence of metabolic syndrome with insulin resistance

  2013cited by this paper
• Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression?

  2013cited by this paper
• Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.

  2012cited by this paper
• No clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma

  2012cited by this paper
• Anhedonia requires MC4 receptor-mediated synaptic adaptations in nucleus accumbens

  2012cited by this paper
• Obesity: lessons from evolution and the environment

  2012cited by this paper
• Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

  2012cited by this paper
• Metabolic syndrome: a brain disease.

  2012cited by this paper
• Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.

  2012cited by this paper
• Day-Night Dip and Early-Morning Surge in Blood Pressure in Hypertension: Prognostic Implications

  2012cited by this paper
• Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities.

  2012cited by this paper
• Clock Genes and Clock-Controlled Genes in the Regulation of Metabolic Rhythms

  2012cited by this paper
• The neuroendocrine circuitry controlled by POMC, MSH, and AGRP.

  2012cited by this paper
• Weighted Effects of Bromocriptine Treatment on Glucose Homeostasisduring Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer

  2012cited by this paper
• Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function

  2012cited by this paper
• Central Prolactin Modulates Insulin Sensitivity and Insulin Secretion in Diabetic Rats

  2012cited by this paper
• Leptin reduces food intake via a dopamine D2 receptor-dependent mechanism.

  2012cited by this paper
• Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity

  2012cited by this paper
• Relationship of Dopamine Type 2 Receptor Binding Potential With Fasting Neuroendocrine Hormones and Insulin Sensitivity in Human Obesity

  2012cited by this paper
• Contribution of the mesolimbic dopamine system in mediating the effects of leptin and ghrelin on feeding

  2012cited by this paper
• 70th Anniversary: Body weight regulation - food, gut and brain signalling Plenary Lecture 1 Contribution of the mesolimbic dopamine system in mediating the effects of leptin and ghrelin on feeding

  2012cited by this paper
• A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas

  2012cited by this paper
• Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy

  2011cited by this paper
• Role of dopamine D2 receptors in ischemia/reperfusion induced apoptosis of cultured neonatal rat cardiomyocytes

  2011cited by this paper
• Circadian clocks in fuel harvesting and energy homeostasis.

  2011cited by this paper
• Circadian disruption and SCN control of energy metabolism

  2011cited by this paper
• Randomized Clinical Trial Assessing the Efficacy and Safety of Bromocriptine-QR when Added to Ongoing Thiazolidinedione Therapy in Patients with Type 2 Diabetes Mellitus

  2011cited by this paper
• Pathophysiology of prediabetes.

  2011cited by this paper
• Central insulin and leptin-mediated autonomic control of glucose homeostasis.

  2011cited by this paper
• Lateral thinking about leptin: a review of leptin action via the lateral hypothalamus.

  2011cited by this paper
• BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists

  2011cited by this paper
• Gut–brain signalling: how lipids can trigger the gut

  2011cited by this paper
• Obesity and shift work: chronobiological aspects

  2010cited by this paper
• Hypothalamic control of energy metabolism via the autonomic nervous system

  2010cited by this paper
• Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients.

  2010cited by this paper
• Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.

  2010cited by this paper
• Neuronal regulation of homeostasis by nutrient sensing

  2010cited by this paper
• Cortisol production rate is similarly elevated in obese women with or without the polycystic ovary syndrome.

  2010cited by this paper
• Seasonal variation in metabolic syndrome prevalence

  2010cited by this paper
• Modulation of the mesolimbic dopamine system by leptin.

  2010cited by this paper
• Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up.

  2010cited by this paper
• Leptin increases striatal dopamine D2 receptor binding in leptin‐deficient obese (ob/ob) mice

  2010cited by this paper
• Hypothalamic Fatty Acid Sensing in the Normal and Disease States

  2010cited by this paper
• Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies

  2010cited by this paper
• Reduced accumbens dopamine in Sprague-Dawley rats prone to overeating a fat-rich diet.

  2010cited by this paper
• Hypothalamic lipotoxicity and the metabolic syndrome.

  2010cited by this paper
• Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes

  2010cited by this paper
• Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.

  2010cited by this paper
• Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

  2010cited by this paper
• Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique

  2009cited by this paper
• Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity.

  2009cited by this paper
• Bromocriptine use and the risk of valvular heart disease

  2009cited by this paper
• HPA axis hyperactivity and attempted suicide in young adult mood disorder inpatients.

  2009cited by this paper
• Seasonal variation in fasting glucose and HbA1c in patients with type 2 diabetes.

  2009cited by this paper
• Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists

  2009cited by this paper
• Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity.

  2009cited by this paper
• Neurogenetics of Dopaminergic Receptor Supersensitivity in Activation of Brain Reward Circuitry and Relapse: Proposing “Deprivation-Amplification Relapse Therapy” (DART)

  2009cited by this paper
• Ventromedial nucleus neurons are less sensitive to leptin excitation in rats bred to develop diet-induced obesity.

  2009cited by this paper
• Adverse metabolic and cardiovascular consequences of circadian misalignment

  2009cited by this paper
• Hormone and glucose signalling in POMC and AgRP neurons

  2009cited by this paper

• Pharmacogenomics-Guided therapeutics in type 2 diabetes: Mechanisms, drug Targets, and precision medicine perspectives

  2026cites this paper
• Molecular Mechanisms of Nicergoline from Ergot Fungus in Blocking Human 5-HT3A Receptor

  2024cites this paper
• Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects

  2023influential citation
• Circadian Dysfunction in Adipose Tissue: Chronotherapy in Metabolic Diseases

  2023cites this paper
• Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review

  2023cites this paper
• Tyrosine Hydroxylase Knockdown at the Hypothalamic Supramammillary Nucleus Area Induces Obesity and Glucose Intolerance

  2023cites this paper
• The circadian rhythm: an influential soundtrack in the diabetes story

  2023cites this paper
• Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events: Overview

  2022cites this paper
• Bromocriptine therapy: Review of mechanism of action, safety and tolerability

  2022cites this paper
• Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine

  2022cites this paper
• Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

  2022influential citation
• Insulin and Leptin Levels in Blood and Brain Structures of Rats with Diet-Induced Obesity and the Effect of Various Drugs on Them

  2022cites this paper
• Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet

  2021cites this paper
• Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats

  2021cites this paper
• Circadian‐timed dopamine agonist treatment reverses high‐fat diet‐induced diabetogenic shift in ventromedial hypothalamic glucose sensing

  2020cites this paper
• Dopaminergic Neuron Lesion at the Area of the Biological Clock Pacemaker, Suprachiasmatic Nuclei (SCN) Induces Metabolic Syndrome in Rats

  2020cites this paper
• Glucose-Lowering Drugs Other than Insulin

  2020cites this paper
• Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

  2019cites this paper
• 50 years since the discovery of bromocriptine

  2018cites this paper
• ANNIVERSARY REVIEW: 50 years since the discovery of bromocriptine.

  2018cites this paper
• Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events

  2018cites this paper
• Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management

  2017cites this paper
• Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin

  2017influential citation
• Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin

  2016cites this paper